SOURCE: Equity News Circuit

Equity News Circuit

May 23, 2013 08:15 ET

Free Research Reports on GILD, MRK, ONCY and PFE Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY--(Marketwired - May 23, 2013) - The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Gilead Sciences, Inc. (NASDAQ: GILD) shares traded in the range of $55.75 to $58.06 Wednesday on volume of over 10.0 million shares traded. The company announced that the European Medicines Agency has accepted its marketing authorization application for its Hepatitis C treatment, Sofosbuvir.

Find out more about Gilead Sciences including full access to the free equity report at: www.BedfordReport.com/GILD

Merck & Co., Inc. (NYSE: MRK) shares have gained approximately 14.0 percent year-to-date. The company announced that it has entered into an accelerated share repurchase agreement with to repurchase $5 billion of Merck's common stock. Merck has repurchased a total of approximately 17.8 million shares during the first four months of the year.

Find out more about Merck & Co. including full access to the free equity report at: www.BedfordReport.com/MRK

Oncolytics Biotech, Inc. (NASDAQ: ONCY) shares traded in the range of $2.64 to $3.06 Wednesday. The company announced that its metastatic melanoma treatment met its primary endpoint in a recent U.S. Phase 2 clinical trial. Shares of Oncolytics have fallen approximately 31 percent year-to-date.

Find out more about Oncolytics Biotech including full access to the free equity report at: www.BedfordReport.com/ONCY

Pfizer Inc. (NYSE: PFE) shares spiked approximately 1.8 percent on nearly double the average daily volume Wednesday. The company announced plans to split off its remaining interest in Zoetis Inc., formerly its animal-medicine unit. Zoetis completed its initial public offering in February 2013.

Find out more about Pfizer including full access to the free equity report at: www.BedfordReport.com/PFE

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information